Ann: Investor Webinar featuring COO, Dr Glover & CMO, Dr Woodard, page-99

I am sure many here aren’t aware that the biotech sector is typically a game with big pharma companies. You gotta have money in the bank to keep that smile on your face when negotiating a deal. Imagine having minimal cash at an urgent level, BP may hit with a lower end type deal just so that the company and Shareholders will survive instead of the whole ship sinks.

The recent CR and acquisition of Azercel are both a fantastic move. Again, With this recent test data we have on hands, our hands are not just full of dance cards, but the board will have a smile of confidence where other BP cannot read what is to come (whether there are talks / negotiation with other players, i.e. competitors)

then we have that other technical paper suggested that even at a low dose of CF33 combination with monoclonal antibody, cancer treatment can be achieved with10 months cancer free. Some who say this is still at concept stage has no idea how big of a deal this is.

GLTAH DYOR